Telix has announced that the TGA has approved the use of Illuccix to select patients for PSMA-targeted radionuclide therapy. …
TGA approves new indication for Telix’s Illuccix to include patient selection for PSMA-targeted therapy
October 9, 2024 Australian Biotech
Latest Video
New Stories
-
TGA approves new indication for Telix’s Illuccix to include patient selection for PSMA-targeted therapy
October 9, 2024 - - Australian Biotech -
Medibank expands four-day work week trial to 500 employees
October 9, 2024 - - Other Health -
Anyone wanting to know how this might work, look to New Zealand's Pharmac
October 9, 2024 - - Latest News -
Wesfarmers Health releases most comprehensive real-time dataset on cardiometabolic health
October 9, 2024 - - Latest News -
Peak bodies align in consensus statement on juvenile arthritis
October 9, 2024 - - Latest News -
The consistent failure to speak out is degrading this critical public health program
October 8, 2024 - - Latest News -
New report reveals significant return from investment in adult vaccination
October 8, 2024 - - Latest News